<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="170976">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870701</url>
  </required_header>
  <id_info>
    <org_study_id>08SARC01</org_study_id>
    <nct_id>NCT00870701</nct_id>
  </id_info>
  <brief_title>Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma</brief_title>
  <official_title>Randomised Multicentric Phase III Study Comparing Observation Versus Post-surgery Radiotherapy After Complete Exeresis With Margins Greater Than or Equal to 1 cm in Soft Tissues Members Sarcoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Soft tissue sarcomas represent less than 1% of malignant tumors in adults and sarcomas
      members represent 60% of them.

      These rare tumors involve complex multidisciplinary care better in centers having expertise.

      Loco-regional therapy strategies have evaluated over time for tumors of members leading to
      propose more often the combination of a large conservative tumor excision with radiotherapy.
      Results have been demonstrated equivalent to those of an amputation in terms of local
      control and survival.

      The local recurrence rate for sarcomas of the members of any kind after surgery with or
      without radiotherapy in the literature varies from 10 to 30%.

      The main objective is to achieve a low recurrence rate while maintaining the function. The
      question remains the possibility of an absence of irradiation in selected cases in a
      de-escalation therapy order.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of local control at 5 years after surgery compared with exclusive post-operative radiotherapy for soft tissue tumors of the members who have surgery with wide excision margins greater than or equal to 10 mm.</measure>
    <time_frame>2021</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the quality of life by questionnaire of quality of life QLCQ30</measure>
    <time_frame>2021</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of acute and late complications</measure>
    <time_frame>2009 to 2021</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2021</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">570</enrollment>
  <condition>Soft Tissue Sarcoma of Members</condition>
  <arm_group>
    <arm_group_label>Absence of Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No Radiotherapy; Simple monitoring without active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>50 grays in 25 fractions of 2 Gys or 50.4 grays in 28 fractions of 1.8 grays</description>
    <arm_group_label>Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>absence of radiotherapy</intervention_name>
    <description>absence of radiotherapy</description>
    <arm_group_label>Absence of Radiotherapy</arm_group_label>
    <other_name>Simple monitoring</other_name>
    <other_name>Observation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Soft tissue sarcoma members histologically confirmed

          -  Tumor primitive complete excision with margins greater than or equal to 10 mm in the
             soft tissue in all directions during the initial surgery.

        A sub-centimeter margin is authorized under an anatomic barrier (fascia, fascia,
        inter-osseous membrane, periosteum), if surgery is R0 a margin sub-centimeter depth is
        allowed for superficial tumors if the underlying fascia RESECTED is not invaded.

          -  Primitive tumors without breaking initial tumor and without tumor residue in the
             systematic recovery in case of incomplete initial excision margins or doubtful

          -  WHO less than or equal to 2

          -  Age greater than or equal to 18 years

          -  Review extension negative (normal chest CT)

          -  Information and monitoring possible

          -  Patient affiliated to social security

        Exclusion Criteria:

          -  Previously treated local sarcoma relapse

          -  Visceral or lymph node metastases

          -  pre-operative treatment (chemotherapy or radiotherapy)

          -  PNET, alveolar rhabdomyosarcoma, Darrier-Ferrand sarcoma

          -  excision margins of less than 10 mm in one direction or doubtful or unspecified,
             except under an anatomic barrier (fascia, fascia, inter-osseous membrane,
             periosteum), if surgery is R0 and tumors if the superficial fascia underlying
             RESECTED is not invaded.

          -  Break-tumor during the initial surgery, or residual tumor at second surgery

          -  Chemotherapy

          -  Delay between surgery R0 margins greater than or equal to 1 cm (initial surgery or
             recovery) and the start of radiotherapy exceeding 8 weeks

          -  History of radiation on the Member

          -  History of cancer (except carcinoma in situ of the cervix and basal cell skin cancer
             or in complete remission for over 5 years)

          -  Pregnant Women

          -  Patients under guardianship or curatorship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine DELANNES, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martine DELANNES, MD</last_name>
    <phone>+33 5 61 42 42 42</phone>
    <email>delannes.martine@claudiusregaud.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Muriel POUBLANC</last_name>
    <phone>+ 33 5 61 42 46 74</phone>
    <email>Poublanc.Muriel@claudiusregaud.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hadji HAMIDOU, MD</last_name>
      <phone>+33 2 41 35 28 77</phone>
    </contact>
    <investigator>
      <last_name>Hadji HAMIDOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy KANTOR, MD</last_name>
      <phone>+33 5 56 33 33 44</phone>
    </contact>
    <investigator>
      <last_name>Guy Kantor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne DELCAMBRE-LAIR, MD</last_name>
      <phone>+33 2 31 45 50 20</phone>
    </contact>
    <investigator>
      <last_name>Corinne DELCAMBRE-LAIR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel LAPEYRE, MD</last_name>
      <phone>+33 4 73 27 81 42</phone>
    </contact>
    <investigator>
      <last_name>Michel LAPEYRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Léon LAGRANGE, Pr.</last_name>
      <phone>+33 1 49 81 45 24</phone>
    </contact>
    <investigator>
      <last_name>Jean-Léon LAGRANGE, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abel CORDOBA LARGO, Md.</last_name>
      <phone>03 20 29 59 59</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Abel CORDOBA LARGO, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Pierre SUNYACH, MD</last_name>
      <phone>+33 4 78 78 28 28</phone>
    </contact>
    <investigator>
      <last_name>Marie-Pierre SUNYACH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence MOUREAU-ZABOTTO, MD</last_name>
      <phone>+33 4 91 22 36 37</phone>
    </contact>
    <investigator>
      <last_name>Laurence MOUREAU-ZABOTTO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier COWEN, MD</last_name>
      <email>didier.cowen@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Didier COWEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier - Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen LLACER-MOSCARDO, MD</last_name>
      <phone>+33 4 67 61 31 42</phone>
    </contact>
    <investigator>
      <last_name>Carmen LLACER-MOSCARDO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Nancy</city>
        <zip>54411</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique BECKENDORF, MD</last_name>
      <phone>+33 3 83 59 84 27</phone>
    </contact>
    <investigator>
      <last_name>Véronique BECKENDORF, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliette THARIAT, Md.</last_name>
      <phone>04 92 03 12 68</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Juliette THARIAT, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal HANZEN, Md.</last_name>
      <phone>02 32 08 25 15</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Chantal HANZEN, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Centre René Gauducheau</name>
      <address>
        <city>Saint Herblain (Nantes)</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augustin MERVOYER, MD</last_name>
      <phone>+33 2 40 67 99 55</phone>
    </contact>
    <investigator>
      <last_name>Augustin MERVOYER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de La Loire</name>
      <address>
        <city>Saint-Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy DE LAROCHE, Md.</last_name>
      <phone>04 77 91 70 00</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Guy DE LAROCHE, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georges NOEL, Pr.</last_name>
      <phone>03 88 25 24 56</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Georges NOEL, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine DELANNES, MD</last_name>
      <phone>+33 5.61.42.42.42</phone>
    </contact>
    <investigator>
      <last_name>Martine Delannes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile LEPECHOUX, MD</last_name>
      <phone>+33 142 11 47 57</phone>
    </contact>
    <investigator>
      <last_name>Cécile LEPECHOUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 26, 2015</lastchanged_date>
  <firstreceived_date>March 26, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sarcoma</keyword>
  <keyword>soft tissue</keyword>
  <keyword>members</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>absence of radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
